NABEL ELIZABETH G 4

What Happened
Elizabeth G. Nabel, a member of Lyell Immunopharma's board, received an award of 9,250 derivative shares reported on Form 4. The award is recorded at $0.00 per share (total reported value $0) and is a compensation grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-10. Filing date: 2026-06-12 (appears timely — filed two days after the transaction).
• Transaction type/code: Award/Grant (A); 9,250 derivative shares; price $0.00; reported value $0.
• Shares owned after transaction: Not disclosed in the provided filing data.
• Footnote (vesting): The shares vest on the earlier of (a) the next annual shareholders’ meeting after June 10, 2026 (or immediately prior if Nabel’s service ends due to not being reelected), or (b) the first anniversary of June 10, 2026 — subject to continuous service through that date.
• No 10b5-1 plan, tax‑withholding or cashless exercise language was provided in the supplied details.

Context
This is a typical director compensation award (likely RSUs or a similar derivative grant) that does not involve immediate cash outlay or sale of stock. Value to the insider (and any impact on holdings) depends on vesting and any later disposition; such awards are routine and do not by themselves indicate a buy or sell signal.